GENERAL15 Sept 2026
350% rally in 3 years, multibagger pharma stock to be in focus on Wednesday | Key details from filing | Stock Market News
Sudarshan Pharma Industries says its plan to buy a 9.50% stake in US-based MedTherapy Biotechnology is still under due diligence. Its two promoters will also pick up 1.50% each. The deal aims to grow its US presence and is expected to close by March 2027. The stock has jumped 42% in 2026, but nothing is final yet.
Key Statutory Highlights
- Sudarshan Pharma Industries is acquiring 24.23 lakh equity shares, or a 9.50% stake, in MedTherapy Biotechnology Inc., USA.
- Its promoters Hemal Mehta and Sachin Mehta will each buy a 1.50% stake, and both purchases are still under due diligence.
- The company expects to complete the acquisition by 31 March 2027, with the price paid in US dollars.
Actionable Advice for Taxpayers / Founders:Wait for the company's official exchange filings confirming the due diligence and MedTherapy board resolution, and speak to a certified expert before acting on this news.
Statutory Disclaimer: TaxQue Shorts are AI-assisted editorial briefs for compliance awareness. This brief has not passed every source check; confirm the original notification before acting. This does not constitute formal legal or CA counsel.
TaxQue News Desk
Share: